Loading…
Roivant Sciences Ltd. and Pulmovant, Inc. announced the results on September 8, 2026.
Roivant Sciences Ltd. and Pulmovant, Inc. announced on 2026-09-08 Roivant Sciences Ltd. announced positive results from the Phase 2 PHocus clinical trial evaluating mosliciguat for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), with results compared to placebo.
-75.9% (-487.1 pg/mL) (nominal p<0.0001). The announcement cited -56.3% (p<0.0001), +35.2 meters (p=0.0027), -53.2% (357.7 pg/mL) (p=0.0002), and 12.1% mosliciguat vs. 18.2% placebo.
Roivant Sciences Ltd. has a free float of 577,466,229 shares and 722,323,015 shares outstanding.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.